Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate from BioNTech and DualityBio, has shown promising results in a Phase II study for advanced endometrial cancer. The treatment achieved a confirmed objective response rate of approximately 49.3% in patients previously treated with immune checkpoint inhibitors. With a median progression-free survival of 8.1 months, the findings were presented at the 2026 SGO Annual Meeting. Regulatory progress includes Fast Track and Breakthrough Therapy designations from the FDA, with plans for a biologics license application in 2026 and ongoing Phase 3 trials. These results suggest potential benefits for patients, including those with lower HER2 expression levels, where current therapies are limited.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://european-biotechnology.com/latest-news/biontech-reports-promising-phase-ii-data-for-uterine-cancer-adc/
